Replies to post #134287 on Biotech Values

[biomaven0]

The expectation is that tivo's S/E profile is better than Nexavar, isn't it?

Yes, it appears to be substantially better based on what they said in the call (consonant with their Phase II safety data, but of course we still need to see the detailed data).

Here is the Nexavar safety data:

http://www.nexavar-us.com/scripts/pages/en/hcp/rcc/nexavar-for-advanced-rcc/second-line-outcomes/target-safety/

(Substantial hand-foot, rash, alopecia, diarrhea, nausea and some hemorrhage, dsypnea, neuropathy)

And here is the Phase II data from Aveo:

http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDMwMDI3fENoaWxkSUQ9NDQ3NDkzfFR5cGU9MQ==&t=1

Aside from the target-based effects (hypertension and hoarseness), tivo has a modest amount of diarrhea and asthenia (negligible amount Grade III):

Asthenia (10%), fatigue (8%), stomatitis (4%), and hand-foot syndrome (4%)

Peter